Podcast brought to you by: Ingenuity Variant Analysis - Identify causal variants from human sequencing data in just hours.
. . . and by Biotix - makers of A BETTER TIP(TM) for Next Gen Sequencing
Christophe Lambert, PhD , CEO, Golden Helix, Inc Bio and Contact Info
Listen (6:56) Beware the lure of solving tough problems for a small market
Listen (8:32) Is Illumina competing with their customers?
Listen (9:37) If the end user isn't buying, no one is selling
Listen (6:36) Learning from our GWAS mistakes
Listen (4:14) Where has Golden Helix found success?
Today we transition from our series on sequencing to one on bioinformatics. Christophe Lambert is the CEO of Golden Helix, a bioinformatics company based in Bozeman, Montana. With some degrees in computer science, Lambert saw early on the potential for IT in bio and began Golden Helix back in 1998, the same year Ingenuity Systems was founded. A research internship led to some funding from Glaxo Welcome and Lambert says he "started writing code in his bedroom" with no one to talk to but his wife.
Lambert's fourteen years in the business combined with his ability to think systematically has given him an insightful perspective on the industry. He's one of the few in this exploding field who acknowledges that the industry is quite small, not yet really making it to the clinic. "When the end user is not buying, no one is selling," he says in today's show. Lambert's impulse is to always look at the macro picture, probing why the science isn't there yet and what societal issues are holding back genomic medicine. I tried to pull him back a bit and get more information on Golden Helix, but half way through the interview, I just went with him. I highly recommend his blog at http://blog.goldenhelix.com/?author=5. This Montana Canadian has something to say.